- Home
- BBIO vs ASND Comparison
BBIO vs ASND Comparison
Compare BBIO & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- ASND
- Stock Information
- Founded
- BBIO 2015
- ASND 2006
- Country
- BBIO United States
- ASND Denmark
- Employees
- BBIO N/A
- ASND N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- ASND Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- ASND Health Care
- Exchange
- BBIO Nasdaq
- ASND Nasdaq
- Market Cap
- BBIO 8.8B
- ASND 9.9B
- IPO Year
- BBIO 2019
- ASND 2015
- Fundamental
- Price
- BBIO $47.27
- ASND $173.50
- Analyst Decision
- BBIO Strong Buy
- ASND Strong Buy
- Analyst Count
- BBIO 16
- ASND 17
- Target Price
- BBIO $61.50
- ASND $222.71
- AVG Volume (30 Days)
- BBIO 2.2M
- ASND 425.7K
- Earning Date
- BBIO 08-05-2025
- ASND 09-02-2025
- Dividend Yield
- BBIO N/A
- ASND N/A
- EPS Growth
- BBIO N/A
- ASND N/A
- EPS
- BBIO N/A
- ASND N/A
- Revenue
- BBIO $127,415,000.00
- ASND $398,509,511.00
- Revenue This Year
- BBIO $106.33
- ASND $79.35
- Revenue Next Year
- BBIO $54.30
- ASND $76.18
- P/E Ratio
- BBIO N/A
- ASND N/A
- Revenue Growth
- BBIO N/A
- ASND 12.06
- 52 Week Low
- BBIO $21.72
- ASND $111.09
- 52 Week High
- BBIO $48.68
- ASND $183.00
- Technical
- Relative Strength Index (RSI)
- BBIO 64.57
- ASND 54.44
- Support Level
- BBIO $45.11
- ASND $160.86
- Resistance Level
- BBIO $47.11
- ASND $175.88
- Average True Range (ATR)
- BBIO 1.40
- ASND 6.40
- MACD
- BBIO -0.26
- ASND -0.42
- Stochastic Oscillator
- BBIO 60.53
- ASND 66.19
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.